Journal Pharmasci (Journal of Pharmacy and Science)
Vol. 9 No. 1 (2024): Journal Pharmasci (Journal of Pharmacy and Science)

Study of Levofloxacin and Cefoperazone-Sulbactam Utilization Cost on Patients with Mild and Moderate Corona Virus Disease- 2019: Studi Biaya Penggunaan Antibiotik Levofloxacin dan Cefoperazone-Sulbactam pada Pasien Corona Virus Disease-2019 Derajat Ringan sampai Sedang

Dyah Ayu Listyaningrum (Akademi Farmasi Surabaya)
Intan Kurnia Permatasari (Akademi Farmasi Surabaya)



Article Info

Publish Date
27 Jun 2024

Abstract

Covid-19 is a highly infectious disease caused by SARS Cov-2. Antibiotics are sometimes given as therapy to patients when there is a secondary bacterial infection. The purpose of this study was to determine the treatment costs associated with using antibiotics Levofloxacin and Cefoperazone Sulbactam for mild to moderate COVID-19 patients at Bhayangkara H.S Samsoeri Mertojoso Hospital in Surabaya. For mild COVID-19 patients who receive levofloxacin antibiotic therapy, the total cost of treatment is IDR. 66,648,632 with a length of stay of 9 days. For patients with moderate degrees of COVID-19, the total cost of treatment is Rp. 81,339,295 with 10 days of hospitalization. For mild COVID-19 patients who receive cefoperazone sulbactam antibiotic therapy, the total cost of treatment is IDR. 81,401,005 with a length of stay of 11 days. For patients with moderate degrees of COVID-19, the total medical costs are Rp. 71,613,107 with 9 days of hospitalization. Based on the evaluation of research results, mild COVID-19 patients can receive levofloxacin antibiotic therapy, while moderate COVID-19 patients can receive cefoperazone sulbactam antibiotic therapy because it is cheaper and results in a shorter length of stay.

Copyrights © 2024






Journal Info

Abbrev

jps

Publisher

Subject

Biochemistry, Genetics & Molecular Biology Chemistry Health Professions Immunology & microbiology Medicine & Pharmacology

Description

Journal of Pharmacy and Science (Pharmasci) publishes full-length original articles and reviews. The scope of the journal is pharmaceutical and basic science, including its research and application. The editors, therefore, welcome contributions on the following topics: 1. Clinical pharmacy 2. ...